title: Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.
abstract: Cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, has been reported to possess diverse biological activities, including anti-proliferative effect on cancer cells. Although CBD is obtained from non-enzymatic decarboxylation of its parent molecule, cannabidiolic acid (CBDA), few studies have investigated whether CBDA itself is biologically active. Results of the current investigation revealed that CBDA inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. It is established that activation of the RhoA signaling pathway leads to inhibition of the mobility of various cancer cells, including MDA-MB-231 cells. The data presented in this report suggest for the first time that as an active component in the cannabis plant, CBDA offers potential therapeutic modality in the abrogation of cancer cell migration, including aggressive breast cancers.
authors.affiliation: Department of Molecular Biology, Daiichi University of Pharmacy, 22-1 Tamagawa-cho, Minami-ku, Fukuoka 815-8511, Japan.
authors.forename: Shuso
authors.initials: S
authors.lastname: Takeda
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Okajima
authors.forename: Hiroko
authors.initials: H
authors.lastname: Miyoshi
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Yoshida
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Tomoko
authors.initials: T
authors.lastname: Okada
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Amamoto
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Watanabe
authors.forename: Curtis J
authors.initials: CJ
authors.lastname: Omiecinski
authors.forename: Hironori
authors.initials: H
authors.lastname: Aramaki
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002186:Cannabinoids / Q000494:pharmacology*; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D015398:Signal Transduction; D054460:rho-Associated Kinases / Q000096:biosynthesis
chemical_list: D000970:Antineoplastic Agents; D002186:Cannabinoids; D004791:Enzyme Inhibitors; D054460:rho-Associated Kinases; D017868:Cyclic AMP-Dependent Protein Kinases; C006884:cannabidiolic acid